Stock Update: Actavis plc (NYSE:ACT) – Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

[PR Newswire] – DUBLIN, April 20, 2015 /PRNewswire/ — Actavis plc (ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug Administration (FDA) has approved an . . . → Read More: Stock Update: Actavis plc (NYSE:ACT) – Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults Similar Articles: Company Update: Agilent Technologies Inc (NYSE:A) – Dako, an Agilent Technologies Company, announces expanded collaboration with Amgen within companion diagnostics Stock Update (NYSE:MRK): Merck expects to be denied approval for sugammadex injection again Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25)